NY0123
NY0123 is a EPAC1 inhibitor. NY0123 significantly inhibits the expression of EPAC1, phosphorylated AKT, phosphorylated ERK1/2 and phosphorylated VEGFR2. NY0123 inhibits angiogenesis and tumor growth of triple-negative breast cancer. NY0123 is applicable to relevant research on triple-negative breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1801911-70-5
- 分子式: C16H13Cl3N4O2
- 分子量:399.66
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
VEGFR2 |
ERK1 |
ERK2 |
EPAC1 |
体内実験
NY0123 (25-100 μM; topical application to CAM; single dose; 48-hour incubation) significantly suppresses angiogenesis in Gallus gallus domesticus embryo CAM models with greater efficacy than ESI-09[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 5-6 weeks old, 4T1 cell xenograft model)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every two days; 14 days
-
Result:Significantly reduced tumor volume and tumor weight compared to DMSO control.
Significantly lowered tumor microvessel density (measured via CD31 IHC staining) and tumor cell proliferation index (measured via Ki67 IHC staining) compared to DMSO control.
Exhibited greater inhibitory effects on tumor volume, tumor weight, MVD, and proliferation index than ESI-09.
Showed no treatment-related organ toxicities via H&E staining of heart, liver, lung, brain, spleen, kidney, and intestine tissues.
-
Animal Model:White leghorn (7-day-old embryo, CAM vascularization model)[1]
-
Dosage:25 μM, 50 μM, 100 μM
-
Administration:topical application to CAM; single dose; 48-hour incubation
-
Result:Significantly reduced CAM microvessel density at 100 μM compared to DMSO control.
Exhibited greater inhibitory effects on angiogenesis at 100 μM than ESI-09 at the same concentration.
- RNA extraction experimental
- Human pluripotent stem cell endothelial-cell differentiation
- Vascular/Branching Fractal Analysis
- Endothelial Tube Formation Assay
- Patient-Derived Xenograft (PDX)
- Patient-Derived Orthotopic Xenograft (PDOX)
- Subcutaneous Cell-Line-Derived Xenograft
- Breast Cancer Modeling
- Endothelial Cell Migration/Angiogenic Sprouting Assay
- Orthotopic Cell-Line Xenograft
化学情報
-
CAS 番号 1801911-70-5
-
分子量 399.66
-
分子式 C16H13Cl3N4O2
-
SMILES
N#CC(=NNC1=CC(Cl)=C(Cl)C(Cl)=C1)C(=O)C2=NOC(=C2)C(C)(C)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
NY0123 関連分類
HY-123795 関連分類
Powered by Bioz